(Q42627777)

English

A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy

scientific article published on January 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Céline Verstuyft

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Xavier Delavenne

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Alexandra Rousseau

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Annie Robert

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Michel Tod

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Bertrand Diquet

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Martine Lebot

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Patrice Jaillon

8

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Laurent Becquemont

9

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

1 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

41-53

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Major bleeding after hospitalization for deep-venous thrombosis.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Pharmacogenetics of warfarin elimination and its clinical implications

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Genetic determinants of response to warfarin during initial anticoagulation

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Identification of the gene for vitamin K epoxide reductase

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

The largest prospective warfarin-treated cohort supports genetic forecasting

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Management and dosing of warfarin therapy

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Estimation of the warfarin dose with clinical and pharmacogenetic data

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Genetic and environmental risk factors for oral anticoagulant overdose

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Pharmacogenetics of acenocoumarol pharmacodynamics.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Comparison of four basic models of indirect pharmacodynamic responses

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Evaluation of different tests based on observations for external model evaluation of population analyses

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Prediction of fluindione maintenance dosage hampered by large intraindividual variability.

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Modeling INR data to predict maintenance fluindione dosage

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Anticoagulant effect and plasma kinetics of fluorophenindione after a single dose in man

1 reference

https://api.crossref.org/works/10.2165%2F11595560-000000000-00000

21 January 2018

Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predicting daily maintenance dose of fluindione, an oral anticoagulant drug.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid and simple micromethod for the quantification of fluindione in human plasma using high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Worldwide management of oral anticoagulant therapy: the ISAM study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking

1 reference

https://pubmed.ncbi.nlm.nih.gov/22149257

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11595560-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Dimensions Publication ID

0 references

release_xdba4n6mzjdkhpkpu36yljtsui

1 reference

https://api.fatcat.wiki/v0/release/xdba4n6mzjdkhpkpu36yljtsui

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42627777&oldid=2205555860"